tradingkey.logo
搜索

Nervgen Pharma Ord Shs

NGEN
添加自选
2.020USD
+0.060+3.06%
收盘 09-24 16:00(美东)
214.50M总市值
亏损市盈率 TTM

关于 Nervgen Pharma Ord Shs 公司

NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.

Nervgen Pharma Ord Shs 简介

公司代码NGEN
公司名称NervGen Pharma Corp
上市日期Mar 13, 2019
CEORogers (Adam H)
员工数量- -
证券类型Ordinary Share
年结日- -
公司地址Suite 1703 - 595 Burrard Street
城市VANCOUVER
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Canada
邮编V7X 1J1
电话16047225361
网址https://www.nervgen.com/
公司代码NGEN
上市日期Mar 13, 2019
CEORogers (Adam H)

Nervgen Pharma Ord Shs公司高管

名称
名称/职务
职务
持股
持股变动
Dr. Randall E. Kaye, M.D.
Dr. Randall E. Kaye, M.D.
Independent Director
Independent Director
168.97K
+5.31%
Dr. Randall E. Kaye, M.D.
Dr. Randall E. Kaye, M.D.
Independent Director
Independent Director
168.97K
+5.31%
Dr. Randall E. Kaye, M.D.
Dr. Randall E. Kaye, M.D.
Independent Director
Independent Director
168.97K
+5.31%
Ms. Krista L. Mckerracher
Ms. Krista L. Mckerracher
Independent Director
Independent Director
45.38K
+38.84%
Ms. Krista L. Mckerracher
Ms. Krista L. Mckerracher
Independent Director
Independent Director
45.38K
+38.84%
Ms. Krista L. Mckerracher
Ms. Krista L. Mckerracher
Independent Director
Independent Director
45.38K
+38.84%
,
,
--
--
Mr. Brian Eric Bayley
Mr. Brian Eric Bayley
Independent Director
Independent Director
--
--
Dr. Harold Martin Punnett
Dr. Harold Martin Punnett
Independent Director
Independent Director
--
--
Mr. William J. (Bill) Adams
Mr. William J. (Bill) Adams
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Randall E. Kaye, M.D.
Dr. Randall E. Kaye, M.D.
Independent Director
Independent Director
168.97K
+5.31%
Dr. Randall E. Kaye, M.D.
Dr. Randall E. Kaye, M.D.
Independent Director
Independent Director
168.97K
+5.31%
Dr. Randall E. Kaye, M.D.
Dr. Randall E. Kaye, M.D.
Independent Director
Independent Director
168.97K
+5.31%
Ms. Krista L. Mckerracher
Ms. Krista L. Mckerracher
Independent Director
Independent Director
45.38K
+38.84%
Ms. Krista L. Mckerracher
Ms. Krista L. Mckerracher
Independent Director
Independent Director
45.38K
+38.84%
Ms. Krista L. Mckerracher
Ms. Krista L. Mckerracher
Independent Director
Independent Director
45.38K
+38.84%

常见问题

Nervgen Pharma Ord Shs的前五大股东是谁?

Nervgen Pharma Ord Shs 的前五大股东如下:Dr. Randall E. Kaye, M.D.

有多少机构持有Nervgen Pharma Ord Shs(NGEN)的股份?

截至2026Q1,共有17家机构持有Nervgen Pharma Ord Shs的股份,合计持有的股份价值约为350.93K,占公司总股份的0.44%。与2025Q4相比,机构持股有所增加,增幅为303132.00。
tradingkey.logo
风险提示:我们的网站和移动应用程序仅提供关于某些投资产品的一般信息。Finsights 不提供财务建议或对任何投资产品的推荐,且提供此类信息不应被解释为 Finsights 提供财务建议或推荐。
投资产品存在重大投资风险,包括可能损失投资的本金,且可能并不适合所有人。投资产品的过去表现并不代表其未来表现。
Finsights 可能允许第三方广告商或关联公司在我们的网站或移动应用程序的任何部分放置或投放广告,并可能根据您与广告的互动情况获得报酬。
© 版权所有: FINSIGHTS MEDIA PTE. LTD. 版权所有